Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JNT
Special Issues
Emerging Strategies in Nanomedicine
share announcement

Emerging Strategies in Nanomedicine

A special issue of Journal of Nanotheranostics (ISSN 2624-845X).

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 7458

Special Issue Editors

Dr. Stephanie Corde

E-Mail Website
Guest Editor
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia
Interests: radiation therapy; synchrotron radiation; radiation dose enhancement; radiation dosimetry; radiation biology; radiation sensitization
Dr. Moeava Tehei

E-Mail Website
Guest Editor
Centre for Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia
Interests: image guided therapy; theranostics; diagnostics; multimodal therapies; nanoparticle design; simulation; radiosensitization

Special Issue Information

Dear Colleagues,

Nanomedicine is an interdisciplinary field of science that combines the principles of nanotechnology and medicine to develop novel therapies, diagnostics, and devices for diagnosing, treating, and preventing diseases. With technological advancement, several emerging nanomedicine strategies have been developed as nanoparticles for therapies (hyperthermia, dose enhancement, targeted drug delivery systems) and diagnostics.

Emerging nanomedicine strategies have tremendous potential to revolutionize medicine and improve patient outcomes.

This Special Issue aims to collect papers that are focused on the recent advancements made in emerging nanomedicine strategies. We invite authors to submit original research or review articles that focus on, but are not limited to, the nanoparticle design and their application in radiosensitization, image-guided therapy, and multimodal therapies.

Dr. Stephanie Corde
Dr. Moeava Tehei
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Nanotheranostics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • image guided therapy
  • theranostics
  • diagnostics
  • multimodal therapies
  • nanoparticle design
  • simulation
  • radiosensitization

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 3191 KiB  
Article
Efficacy of 15 nm Gold Nanoparticles for Image-Guided Gliosarcoma Radiotherapy
by Elette Engels, Michael Lerch, Stéphanie Corde and Moeava Tehei
J. Nanotheranostics 2023, 4(4), 480-495; https://doi.org/10.3390/jnt4040021 - 26 Oct 2023
Cited by 1 | Viewed by 1779
Abstract
Targeted brain cancer treatments are sorely needed to improve long-term prognosis, particularly for gliosarcoma and glioblastoma patients. Gold nanoparticles (GNPs) have unique properties including high atomic number, biocompatibility, and small size for cancer cell internalization. GNPs are consequently an ideal candidate for improved [...] Read more.
Targeted brain cancer treatments are sorely needed to improve long-term prognosis, particularly for gliosarcoma and glioblastoma patients. Gold nanoparticles (GNPs) have unique properties including high atomic number, biocompatibility, and small size for cancer cell internalization. GNPs are consequently an ideal candidate for improved cancer targeting using image-guided radiotherapy. This work investigated 15 nm AuroVistTM GNPs for image-guided gliosarcoma radiotherapy and identified optimum GNP concentrations. The GNPs were found to be 15–20 nm using optical surface plasmon resonance absorption, with a (41.3 ± 0.3) nm hydrodynamic diameter. Confocal imaging showed that 50–500 µg/mL of the GNPs was well-internalized into the 9L cells within 24–48 h. γ-H2AX assays showed that 50–500 µg/mL of the GNPs radiosensitized the 9L cells irradiated with 125 and 150 kVp X-rays. However, only 500 µg/mL of the GNPs produced significant long-term dose enhancement with 150 kVp X-rays (with a sensitization enhancement ratio at 10% survival of 1.43, and 1.13 with 50 µg/mL) using clonogenic assay. CT imaging of the GNPs in the 9L tumors in Fischer rats further showed that GNP concentrations above 500 µg/mL were required to distinguish the tumor from the brain, and the GNPs were detected 48 h after injection. These promising results indicate that the GNPs can be used for selective gliosarcoma treatment with image-guided X-ray radiotherapy at concentrations above 500 µg/mL. Full article
(This article belongs to the Special Issue Emerging Strategies in Nanomedicine)
►▼ Show Figures

Graphical abstract

20 pages, 5542 KiB  
Article
Convolutional Neural Network Classification of Exhaled Aerosol Images for Diagnosis of Obstructive Respiratory Diseases
by Mohamed Talaat, Jensen Xi, Kaiyuan Tan, Xiuhua April Si and Jinxiang Xi
J. Nanotheranostics 2023, 4(3), 228-247; https://doi.org/10.3390/jnt4030011 - 26 Jun 2023
Cited by 7 | Viewed by 1657
Abstract
Aerosols exhaled from the lungs have distinctive patterns that can be linked to the abnormalities of the lungs. Yet, due to their intricate nature, it is highly challenging to analyze and distinguish these aerosol patterns. Small airway diseases pose an even greater challenge, [...] Read more.
Aerosols exhaled from the lungs have distinctive patterns that can be linked to the abnormalities of the lungs. Yet, due to their intricate nature, it is highly challenging to analyze and distinguish these aerosol patterns. Small airway diseases pose an even greater challenge, as the disturbance signals tend to be weak. The objective of this study was to evaluate the performance of four convolutional neural network (CNN) models (AlexNet, ResNet-50, MobileNet, and EfficientNet) in detecting and staging airway abnormalities in small airways using exhaled aerosol images. Specifically, the model’s capacity to classify images inside and outside the original design space was assessed. In doing so, multi-level testing on images with decreasing similarities was conducted for each model. A total of 2745 images were generated using physiology-based simulations from normal and obstructed lungs of varying stages. Multiple-round training on datasets with increasing images (and new features) was also conducted to evaluate the benefits of continuous learning. Results show reasonably high classification accuracy on inbox images for models but significantly lower accuracy on outbox images (i.e., outside design space). ResNet-50 was the most robust among the four models for both diagnostic (2-class: normal vs. disease) and staging (3-class) purposes, as well as on both inbox and outbox test datasets. Variation in flow rate was observed to play a more important role in classification decisions than particle size and throat variation. Continuous learning/training with appropriate images could substantially enhance classification accuracy, even with a small number (~100) of new images. This study shows that CNN transfer-learning models could detect small airway remodeling (<1 mm) amidst a variety of variants and that ResNet-50 can be a promising model for the future development of obstructive lung diagnostic systems. Full article
(This article belongs to the Special Issue Emerging Strategies in Nanomedicine)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

23 pages, 832 KiB  
Review
An Overview of Nanotherapeutic Drug Delivery Options for the Management of Glioblastoma
by William H. Pentz, Vincenzo J. Pizzuti, Matthew E. Halbert, Tritan J. Plute, Paul R. Lockman and Samuel A. Sprowls
J. Nanotheranostics 2023, 4(3), 323-345; https://doi.org/10.3390/jnt4030015 - 1 Aug 2023
Cited by 2 | Viewed by 3073
Abstract
Glioblastoma is the most common primary, malignant brain tumor that remains uniformly lethal in nearly all cases as a result of extreme cellular heterogeneity, treatment resistance, and recurrence. A major hurdle in therapeutic delivery to brain tumors is the blood–brain barrier (BBB), which [...] Read more.
Glioblastoma is the most common primary, malignant brain tumor that remains uniformly lethal in nearly all cases as a result of extreme cellular heterogeneity, treatment resistance, and recurrence. A major hurdle in therapeutic delivery to brain tumors is the blood–brain barrier (BBB), which is the tightly regulated vascular barrier between the brain parenchyma and systemic circulation that prevents distribution of otherwise beneficial chemotherapeutics to central nervous system tumors. To overcome the obstacle of drug delivery beyond the BBB, nanoparticle formulations have come to the forefront, having demonstrated success in preclinical observations, but have not translated well into the clinical setting. In summary, this review article discusses brain tumors and challenges for drug delivery caused by the BBB, explores the benefits of nanoparticle formulations for brain tumor delivery, describes the characteristics these formulations possess that make them attractive therapeutic strategies, and provides preclinical examples that implement nanoparticles within glioma treatment regimens. Additionally, we explore the pitfalls associated with clinical translation and conclude with remarks geared toward overcoming these issues. Full article
(This article belongs to the Special Issue Emerging Strategies in Nanomedicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop